EUVIMEDEUVIMED entdecken
Crossref

Neutrophil-derived nanovesicles deliver IL-37 to mitigate renal ischemia-reperfusion injury via endothelial cell targeting

Wenjie Ma, Di Wu, Chengcheng Long, Jingyu Liu, Luwei Xu, Liuhua Zhou, Quanliang Dou, Yuzheng Ge, Changcheng Zhou, Ruipeng Jia

Journal of Controlled Release · 2024-06 · 370 · 66-81

DOI: 10.1016/j.jconrel.2024.04.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-06. Verfasst von Wenjie Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Interleukin-1, Endothelial Cells, Kidney. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal ischemia-reperfusion injury (IRI) is one of the most important causes of acute kidney injury (AKI). Interleukin (IL)-37 has been suggested as a novel anti-inflammatory factor for the treatment of IRI, but its application is still limited by its low stability and delivery efficiency. In this study, we reported a novel engineered method to efficiently and easily prepare neutrophil membrane-derived vesicles (N-MVs), which could be utilized as a promising vehicle to deliver IL-37 and avoid the potential side effects of neutrophil-derived natural extracellular vesicles. N-MVs could enhance the stability of IL-37 and targetedly deliver IL-37 to damaged endothelial cells of IRI kidneys via P-selectin glycoprotein ligand-1 (PSGL-1). In vitro and in vivo evidence revealed that N-MVs encapsulated with IL-37 (N-MV@IL-37) could inhibit endothelial cell apoptosis, promote endothelial cell proliferation and angiogenesis, and decrease inflammatory factor production and leukocyte infiltration, thereby ameliorating renal IRI. Our study establishes a promising delivery vehicle for the treatment of renal IRI and other endothelial damage-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reperfusion InjuryInterleukin-1Endothelial CellsKidneyNeutrophilsAnimalsMaleHumansMice, Inbred C57BLApoptosisHuman Umbilical Vein Endothelial CellsMembrane GlycoproteinsCell ProliferationAcute Kidney InjuryMiceNanoparticles

Stichwörter der Autor:innen

Acute kidney injuryInterleukin 37Ischemia-reperfusion injuryNanovesiclesNeutrophil membrane

Substanzen

Interleukin-1P-selectin ligand proteinMembrane GlycoproteinsIL37 protein, human

Autor:innen und Institutionen

  • Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China.
  • Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. Electronic address: zhoucc@njmu.edu.cn.
  • Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. Electronic address: urojiarp@njmu.edu.cn.

Zitieren

APA

Ma, W., Wu, D., Long, C., Liu, J., Xu, L., Zhou, L., Dou, Q., Ge, Y., Zhou, C., & Jia, R. (2024). Neutrophil-derived nanovesicles deliver IL-37 to mitigate renal ischemia-reperfusion injury via endothelial cell targeting. Journal of Controlled Release, 370, 66-81. https://doi.org/10.1016/j.jconrel.2024.04.025

Vancouver

Ma W, Wu D, Long C, Liu J, Xu L, Zhou L, et al. Neutrophil-derived nanovesicles deliver IL-37 to mitigate renal ischemia-reperfusion injury via endothelial cell targeting. Journal of Controlled Release. 2024;370:66-81. doi:10.1016/j.jconrel.2024.04.025

BibTeX
@article{Ma2024,
  author = {Ma, Wenjie and Wu, Di and Long, Chengcheng and Liu, Jingyu and Xu, Luwei and Zhou, Liuhua and Dou, Quanliang and Ge, Yuzheng and Zhou, Changcheng and Jia, Ruipeng},
  title = {Neutrophil-derived nanovesicles deliver IL-37 to mitigate renal ischemia-reperfusion injury via endothelial cell targeting},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {370},
  pages = {66--81},
  doi = {10.1016/j.jconrel.2024.04.025}
}
Kostenlos starten →